Gene and Genome Editing represent ground-breaking technologies that enable precise modifications to the genetic material of organisms. These technologies have revolutionized various fields, including biomedicine, agriculture, and biotechnology, by offering unprecedented opportunities for manipulating DNA sequences with high efficiency and accuracy. Gene editing involves making targeted modifications to specific genes within an organism's genome. This is typically achieved using programmable nucleases, such as CRISPR-Cas9, zinc finger nucleases (ZFNs), or transcription activator-like effector nucleases (TALENs), which can be engineered to recognize and cleave specific DNA sequences. Once the DNA is cleaved, the cell's natural repair mechanisms, such as non-homologous end joining (NHEJ) or homology-directed repair (HDR), can be exploited to introduce desired genetic changes. Genome editing, on the other hand, involves making modifications to the entire genome of an organism. This can include large-scale alterations, such as chromosomal rearrangements or deletions, as well as precise modifications to multiple genes simultaneously. Genome editing technologies offer powerful tools for studying gene function, genetic pathways, and complex traits in various organisms, from model organisms like mice and fruit flies to agriculturally important crops and livestock species.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Will be updated soon...
Vasiliki E Kalodimou, European University-Cyprus Ltd, Cyprus
Title : Will be updated soon...
Nagy Habib, Imperial College London, United Kingdom
Title : Will be updated soon...
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : Advanced 3D tissue models: Pioneering tools for investigating health and disease
Lucie Bacakova, Institute of Physiology of the Czech Academy of Sciences, Czech Republic
Title : Developing iPSC-derived 3D Outer Blood-Retinal Barrier Disease Models of Choroideremia for Gene Therapy Evaluation
Aradhana Kasimsetty, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), United States